Atay Oguzhan sold $260K of BLLN (indirect holdings)

Atay Oguzhan (Chairman and CEO) sold 2,667 indirectly-held shares of BillionToOne, Inc. (BLLN) at $97.61 ($0.26M total) on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Oct 14, 2026, 10:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The insider sale is modest but may influence short‑term sentiment for BLLN.

02

Market read

A routine insider sell by the CEO, modest in size, offers limited trading impetus.

03

What to watch

Potential upcoming corporate events or financing needs not disclosed.

Relevance 3/10Novelty 3/10Timing: post‑market filing

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

Chairman and CEO Atay Oguzhan sold 2,667 shares for $260,326 via a 10b5-1 plan, reducing his stake to 151,835 shares.

Expected impact

likely modest pressure as market prices in the insider sell.

Evidence & confidence

The sale is modest in size for a micro‑cap and executed under a pre‑arranged plan, limiting informational content but still a sell signal.

Market effects

Minimal impact on the broader biotech sector.

Limited to U.S. micro‑cap investors.

None

Counterpoint

The sale could be routine and not indicative of future performance.

Key entities

  • BillionToOne, Inc.

    US‑listed biotech firm (ticker BLLN).

  • Atay Oguzhan

    Chairman and CEO of BillionToOne, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.